Breast Cancer | Specialty

Breast Implant-Associated ALCL Understanding and Treatment Evolves

May 1st 2020

Lloyd B. Gayle, MD, discusses the current treatment of patients with breast implant–associated ALCL and remaining questions that need to be addressed.

Dr. O'Regan on Breast Cancer Treatment Considerations During the COVID-19 Crisis

May 1st 2020

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

Marvels in Medicine: Dr. Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer

April 30th 2020

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Imaging Plus Elastography Enhances Surgical Margin Assessment in Breast Cancer

April 30th 2020

Quantitative microelastography demonstrated increased sensitivity, specificity, and accuracy in detecting positive surgical margins in combination with optimal coherence tomography versus optimal coherence tomography alone in women who received breast-conserving surgery.

Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer

April 29th 2020

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC

April 28th 2020

The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.

Adding Durvalumab/Olaparib to Neoadjuvant Chemo Improves pCR in High-Risk HER2-Negative Breast Cancer

April 28th 2020

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

Talazoparib Improves QOL, But Not OS in Advanced BRCA1/2+ Breast Cancer

April 28th 2020

Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.

SKCC Welcomes Dr. Kristin Brill as Enterprise Director of Breast Oncology

April 27th 2020

Breast surgeon Kristin L. Brill MD, has joined the Sidney Kimmel Cancer Center – Jefferson Health as Enterprise Director of Breast Oncology.

FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

April 27th 2020

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Dr. Graff on the FDA Approval of Sacituzumab Govitecan in TNBC

April 22nd 2020

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).

Closing Thoughts on Metastatic Breast Cancers

April 22nd 2020

Assessing the Value of Personalized Treatment in mBC

April 22nd 2020

Considerations for NGS Testing in mTNBC

April 22nd 2020

Treatment Options in Metastatic TNBC

April 22nd 2020

Role of PARP Inhibition and I/O Therapy in TNBC

April 22nd 2020

IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

April 22nd 2020

Sequencing of Therapy in R/R HER2+ mBC

April 22nd 2020

SOPHIA Trial in R/R HER2+ mBC

April 22nd 2020

HER2CLIMB and NALA Trials: R/R HER2+ mBC

April 22nd 2020